Clinically compatible advances in blood-derived endothelial progenitor cell isolation and reprogramming for translational applications

•Clinically-compatible advances in EPC isolation and reprogramming.•Reduced blood-sampling volumes from 80 mL to 10 mL allowing wider use of EPCs.•Unlike other blood-derived cells, EPCs can be reprogrammed with RNA.•EPC-RNA-iPSCs maybe clinically translatable, carrying minimal chromosomal changes.